eISSN: 2688-6650
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


LCZ696: Review of a Novel Agent in Treatment of Congestive Heart Failure

Miraie Wardi, Mohamed Teleb, Priyanka Wani, Marco Bustamante-Bernal, Hasan J. Salameh

Department of Internal Medicine, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, TX, USA

Med Sci Rev 2015; 2:24-31

DOI: 10.12659/MSRev.894178

Available online:

Published: 2015-04-21


ABSTRACT: Despite advances in diagnosis and medical management, congestive heart failure remains a leading cause of hospitalization and the most common cause of hospitalization in the elderly. Mainstays of medical therapy include diuretics for symptomatic relief, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), and beta-blockers to improve mortality associated with congestive heart failure. Recent studies have investigated the efficacy of LCZ696, a novel ARB-neprilysin inhibitor, in the treatment of hypertension and congestive heart failure and have demonstrated its efficacy in reducing blood pressure and morbidity and mortality associated with congestive heart failure.
The purpose of this review is to discuss the efficacy of LCZ696 as a potential pharmacological agent to treat congestive heart failure.

Keywords: angiotensin receptor antagonists, Angiotensin-Converting Enzyme Inhibitors, Heart Failure